ストックスクリーナーアプリを入手
0.9112
2.92%
-0.0274
プレマーケット:
.93
0.0188
+2.06%
Ocugen Inc (OCGN) 最新ニュース
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Nasdaq Health Care Index (IXHC) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Ocugen: Q3 Earnings Snapshot - New Haven Register
Ocugen, Inc. (OCGN) Quarterly 10-Q Report - Quartzy
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Ocugen Inc. - Quantisnow
HC Wainwright Has Pessimistic View of Ocugen FY2024 Earnings - MarketBeat
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Present Innovations at Nasdaq Clinical Showcase - TipRanks
Navigating 4 Analyst Ratings For Ocugen - Benzinga
Ocugen (NASDAQ:OCGN) Given Buy Rating at HC Wainwright - MarketBeat
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MyChesCo
Earnings call: Ocugen outlines progress in ophthalmology trials, financials - Investing.com
Earnings call: Ocugen outlines progress in ophthalmology trials, financials By Investing.com - Investing.com Australia
Ocugen, Inc. (NASDAQ:OCGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen: Progress in Gene Therapy and Financial Outlook - TipRanks
Ocugen (OCGN) Q3 2024 Earnings Call Transcript - The Motley Fool
OCGN Earnings: Ocugen’s Q3 Results Disappoint - TipRanks
Ocugen receives $30M credit facility to fund, allocate resources across company - Pennsylvania Business Report
Ocugen reports Q3 revenue $1.136M, consensus $300,000 - TipRanks
Ocugen Provides Business Update with Third Quarter 2024 Financial Results - Ocugen
Ocugen Secures $65M Financing, Extends Runway to 2026 as Gene Therapy Trials Advance | OCGN Stock News - StockTitan
Ocugen (NASDAQ:OCGN) soars 19% this week, taking one-year gains to 193% - Simply Wall St
A Preview Of Ocugen's Earnings - Benzinga
Ocugen Secures $30 Million In Debt Funding - citybiz
Ocugen Secures $30 Million in Debt Funding - Ocugen
Ocugen, Inc. Secures $30 Million in Debt Funding - Marketscreener.com
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Vanguard Group Inc's Strategic Acquisition of Shares in Ocugen I - GuruFocus.com
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MSN
Ocugen (OCGN) Set to Announce Earnings on Friday - MarketBeat
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163% - Yahoo Finance
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Ocugen
Ocugen Clinical Showcase Highlighting Progress in Retinal - GlobeNewswire
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):